The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.

"raw sequencing data and a matrix containing raw counts were submitted to the geo repository (accession number gse198488).; data availability the rna-sequencing data generated in this study were deposited in ncbi gene expression omnibus (geo accession gse198488). data availability the rna-sequencing data generated in this study were deposited in ncbi gene expression omnibus (geo accession gse198488"

"Competing interests GSdA was previously supported by a research grant from Carrick Therapeutics Ltd to CLB. EO is funded by a MRC iCASE Enterprise studentship in partnership with Carrick Therapeutics Ltd. S Ali is a named inventor on CDK7 inhibitor patents that have been licensed to Carrick Therapeutics Ltd and has received royalty payments, shares, and research funding from Carrick Therapeutics. MJF is a named inventor on CDK7 inhibitor patents that have been licensed to Carrick Therapeutics Ltd and has received royalty payments from Carrick Therapeutics. AKB and EC are/were at the time of this study employees of Carrick Therapeutics. The following authors declare that they have no competing interests: TAC, AV-C, KKG, LP, S Ang, AO, DC, C-FL, DAL."

"Funding This work was supported by the Medical Research Council [grant numbers MR/N014103/1 and MR/R015732/1]; the Imperial College London President’s PhD Scholarship scheme; Prostate Cancer UK [grant numbers RIA19-ST2-004 and RIA17-ST2-001]; and the Cancer Research UK Imperial Centre."